{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T05:29:20Z","timestamp":1757309360409,"version":"3.44.0"},"reference-count":6,"publisher":"BMJ","issue":"9","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["DTB"],"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>\n                  <jats:bold>Overview of:<\/jats:bold>\nSanter M, Lawrence M, Renz S, et al. Effectiveness of spironolactone for women with acne vulgaris (SAFA) in England and Wales: pragmatic, multicentre, phase 3, double blind, randomised controlled trial. BMJ. 2023;381:e074349.\n<\/jats:p>","DOI":"10.1136\/dtb.2023.000040","type":"journal-article","created":{"date-parts":[[2023,7,19]],"date-time":"2023-07-19T13:21:02Z","timestamp":1689772862000},"page":"132-132","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Spironolactone for acne in women"],"prefix":"10.1136","volume":"61","member":"239","published-online":{"date-parts":[[2023,7,19]]},"reference":[{"key":"2025082701123472000_61.9.132.1","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2022-074349","article-title":"Effectiveness of spironolactone for women with acne vulgaris (SAFA) in England and Wales: pragmatic, multicentre, phase 3, double blind, randomised controlled trial","volume":"381","author":"Santer","year":"2023","journal-title":"BMJ"},{"key":"2025082701123472000_61.9.132.2","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-053876","article-title":"Spironolactone for adult female Acne (SAFA): protocol for a double-blind, placebo-controlled, phase III randomised study of spironolactone as systemic therapy for acne in adult women","volume":"11","author":"Renz","year":"2021","journal-title":"BMJ Open"},{"key":"2025082701123472000_61.9.132.3","unstructured":"National Institute for Health and Care Excellence . Acne Vulgaris: management (NG198) [online]. 2023. Available: https:\/\/www.nice.org.uk\/guidance\/ng198 [Accessed 6 Jul 2023]."},{"key":"2025082701123472000_61.9.132.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.12.037"},{"key":"2025082701123472000_61.9.132.5","article-title":"Spironolactone versus placebo or in combination with steroids for hirsutism and\/or acne","volume":"2","author":"Brown","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"2025082701123472000_61.9.132.6","unstructured":"British Association of Dermatologists . Patient information leaflet: spironolactone [online]. 2022. Available: https:\/\/cdn.bad.org.uk\/uploads\/2021\/12\/22095851\/Spironolactone-PIL-Nov-2022.pdf [Accessed 6 Jul 2023]."}],"container-title":["Drug and Therapeutics Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/dtb.2023.000040","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T08:12:46Z","timestamp":1756282366000},"score":1,"resource":{"primary":{"URL":"https:\/\/dtb.bmj.com\/lookup\/doi\/10.1136\/dtb.2023.000040"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,19]]},"references-count":6,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023,8,30]]},"published-print":{"date-parts":[[2023,9]]}},"alternative-id":["10.1136\/dtb.2023.000040"],"URL":"https:\/\/doi.org\/10.1136\/dtb.2023.000040","relation":{},"ISSN":["0012-6543","1755-5248"],"issn-type":[{"type":"print","value":"0012-6543"},{"type":"electronic","value":"1755-5248"}],"subject":[],"published":{"date-parts":[[2023,7,19]]}}}